Century Therapeutics
IPSC | NASDAQ
$1.64
-$0.01 (-0.61%)
At close: Nov 16, 2026, 4:00 PM ET
$1.64
$0.00 (-0.18%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Century Therapeutics Company Profile
Company profile explainedCompany Profile
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Brent Pfeiffenberger | President, Chief Executive Officer & Chairman |
| Megan Bilson | Chief People Officer |
| Chad A. Cowan | Chief Scientific Officer |
| Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary |
| Elizabeth Devlin | Vice President & Head of Development |
| Gregory Russotti | Chief Technology & Manufacturing Officer |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property |
| Michael Naso | Senior Vice President of Cell Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 4 | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 3 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 8-K | Current Report |
Century Therapeutics
| Country | United States |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Brent Pfeiffenberger |
Contact Details
25 North 38th Street Philadelphia,
Pennsylvania 19104 United States
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850119 |
| CUSIP Number | 15673T100 |
| ISIN Number | US15673T1007 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove IPSC